NASDAQ:BBLG Bone Biologics (BBLG) Stock Price, News & Analysis $0.50 +0.00 (+0.98%) Closing price 09/25/2026 04:00 PM EasternExtended Trading$0.48 -0.01 (-2.22%) As of 09/25/2026 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsNews and TrendsOwnershipSEC Filings About Bone Biologics Stock (NASDAQ:BBLG) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Bone Biologics alerts:Sign Up Key Stats Today's Range$0.47▼$0.5050-Day Range$0.48▼$1.1252-Week Range$0.43▼$2.89Volume57,572 shsAverage Volume306,290 shsMarket Capitalization$1.37 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Bone Biologics Corporation is a medical device and biotechnology company focused on developing regenerative products for bone repair and reconstruction. Its work centers on NELL-1, a recombinant protein intended to stimulate bone formation and support the healing of skeletal defects. The company is developing NELL-1-based bone graft substitutes and delivery systems, including applications designed for spinal fusion and other orthopedic procedures. These products are intended to provide alternatives or complements to traditional bone graft materials by promoting the body’s own bone-regeneration processes. Bone Biologics is a development-stage company, and its technologies remain subject to clinical, regulatory and commercial development requirements. The company’s primary focus is the advancement of its bone-regeneration platform for use in the United States and potentially other markets.AI Generated. May Contain Errors. Read More Bone Biologics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks23rd Percentile Overall ScoreBBLG MarketRank™: Bone Biologics scored higher than 23% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingBone Biologics has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageBone Biologics has only been the subject of 1 research reports in the past 90 days.Read more about Bone Biologics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Bone Biologics are expected to grow in the coming year, from ($1.23) to ($0.67) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Bone Biologics is -0.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Bone Biologics is -0.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBone Biologics has a P/B Ratio of 0.17. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Bone Biologics' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.37% of the float of Bone Biologics has been sold short.Short Interest Ratio / Days to CoverBone Biologics has a short interest ratio ("days to cover") of 0.84, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Bone Biologics has recently decreased by 3.10%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBone Biologics does not currently pay a dividend.Dividend GrowthBone Biologics does not have a long track record of dividend growth. News and Social Media3.0 / 5News SentimentN/A News SentimentBone Biologics has a news sentiment score of 1.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.72 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for Bone Biologics this week, compared to 2 articles on an average week. Company Ownership0.6 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Bone Biologics insiders have not sold or bought any company stock.Percentage Held by Insiders5.00% of the stock of Bone Biologics is held by insiders.Percentage Held by Institutions34.30% of the stock of Bone Biologics is held by institutions.Read more about Bone Biologics' insider trading history. Receive BBLG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bone Biologics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BBLG Stock News HeadlinesBone Biologics Expands Trial SitesSeptember 8, 2026 | globenewswire.comBone Biologics to Participate in the H.C. Wainwright 28th Annual Global Investment ConferenceSeptember 3, 2026 | globenewswire.comIran War WARNING: Something Just ChangedA powerful Middle Eastern government is reportedly asking Trump for U.S. military help against Iran backed forces. One writer says the request echoes a secret January meeting outside Washington, D.C., where an anonymous source described American military protection as part of something much bigger, involving Trump, Iran, and potentially trillions of dollars.September 26 at 1:00 AM | Banyan Hill Publishing (Ad)BBLG Efficiency Improves as Crucial Trials AdvanceAugust 17, 2026 | finance.yahoo.comBone Biologics extends rhNELL-1 validated shelf life to 32 months as NB1 study advancesAugust 12, 2026 | msn.comBone Biologics Achieves 32-Month Validated Shelf Life for rhNELL-1August 12, 2026 | globenewswire.comBone Biologics Issues Mid-Year Shareholder Update Highlighting Progress Across 2026 PrioritiesJuly 23, 2026 | globenewswire.comBBLG Secures Financing for Critical TrialsJuly 8, 2026 | finance.yahoo.comSee More Headlines BBLG Stock Analysis - Frequently Asked Questions How have BBLG shares performed this year? Bone Biologics' stock was trading at $1.45 at the start of the year. Since then, BBLG shares have decreased by 65.8% and is now trading at $0.4960. How were Bone Biologics' earnings last quarter? Bone Biologics Corp. (NASDAQ:BBLG) issued its quarterly earnings data on Friday, August, 14th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by $0.04. When did Bone Biologics' stock split? Bone Biologics's stock reverse split on the morning of Tuesday, June 10th 2025.The 1-6 reverse split was announced on Monday, June 9th 2025. The number of shares owned by shareholders was adjusted after the market closes on Monday, June 9th 2025. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split. When did Bone Biologics IPO? Bone Biologics (BBLG) raised $8 million in an initial public offering on Wednesday, October 13th 2021. The company issued 1,510,455 shares at $5.25 per share. How do I buy shares of Bone Biologics? Shares of BBLG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Bone Biologics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Bone Biologics investors own include Pfizer (PFE), NVIDIA (NVDA), Meta Platforms (META), PayPal (PYPL), Advanced Micro Devices (AMD), Canopy Growth (CGC) and Cisco Systems (CSCO). Company Calendar Last Earnings8/14/2026Today9/25/2026Next Earnings (Estimated)11/13/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (13m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 BBLG's financial health is in the Red zone, according to TradeSmith. BBLG has been in this zone for over 13 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Healthcare Equipment & Supplies Sub-IndustryHealthcare Equipment Current SymbolNASDAQ:BBLG Previous SymbolNASDAQ:BBLG CIK1419554 Webwww.bonebiologics.com Phone781-552-4452FaxN/AEmployees2Year Founded2004Profitability EPS (Trailing Twelve Months)($1.37) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$3.11 million Net MarginsN/A Pretax MarginN/A Return on Equity-57.87% Return on Assets-53.65% Debt Debt-to-Equity RatioN/A Current Ratio8.67 Quick Ratio8.67 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.00 per share Price / Book0.17Miscellaneous Outstanding Shares2,760,000Free Float2,618,000Market Cap$1.37 million OptionableNot Optionable Beta0.89 Social Links 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NASDAQ:BBLG) was last updated on 9/26/2026 by MarketBeat.com Staff. From Our PartnersA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredShocking new footage just releasedGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | SponsoredThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredAnalyst nicknamed “The Prophet” issues new warning for AmericaWhitney Tilson exposed a major company on 60 Minutes in an Emmy-winning investigation - the stock lost nearly ...Stansberry Research | Sponsored"How Much Can I Actually Spend Each Year With $2.5M Saved?"Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you...SmartAsset | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredMake this "Money Move" Before Midterms November 3rdAddison Wiggin has interviewed Warren Buffett, questioned two former Treasury Secretaries, and warned of the 2...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bone Biologics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bone Biologics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
